Company intelligence / Profile preview

Nanjing Kati Medical Technology

Nanjing, Jiangsu, China

Ownership: Private
Employees: ~50
Development stage: Other

Overview

The company has advanced multiple autologous CAR-T therapies into early clinical development, with lead programs in Phase 2 (anti-CLDN18.2 CAR-T for solid tumors) and promising safety and efficacy data for CD19-KIRS2/Dap12-BB CAR-T in adults with r/r B-ALL, demonstrating complete responses and a favorable safety profile[7].

Therapeutic areas: Oncology
Modalities: CAR-T cell therapyCell therapy
Industry: Biotech

Drug pipeline

1 asset

DLL3-TREM1/DAP12 CAR-T

Preclinical

Partnerships

Nanjing Shenghe Pharmaceutical

Beyond the preview

Go deeper on Nanjing Kati Medical Technology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nanjing Kati Medical Technology.

Explore the full profile